BridgeMD
New treatment option for Uterine Cervical Neoplasms
Official title Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer
ClinicalTrials.gov ID: NCT05735145
What this study is testing
What is paclitaxel combined with platinum?
paclitaxel combined with platinum is an investigational medicine, being studied as a potential treatment for uterine cervical neoplasms.
Also referred to as Adjuvant chemotherapy with paclitaxel combined with platinum.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study carried out a prospective, randomized, controlled clinical study under the background of intensity-modulated radiation therapy and three-dimensional afterloading therapy. By comparing simultaneous intensity-modulated radiotherapy and chemotherapy combined with adjuvant chemotherapy and simultaneous intensity-modulated radiotherapy and chemotherapy alone, based on the 2018 FIGO staging The clinical efficacy of locally advanced cervical cancer further clarifies the role of adjuvant chemotherapy in locally advanced cervical cancer.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75, women only
You may be able to join if
- Cervical cancer confirmed by histopathology incloud squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma
- FIGO stage IB3, IIA2, IIB-IVA patients in 2018
- Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional...
- Aged 18-75 years
- PS score 0-1
You likely can't join if
- Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional...
- Patients who have received neoadjuvant chemotherapy and surgery
- Patients with cognitive impairment
- Patients with any distant metastases
- Patients with any other malignancy within 5 years
- Any other disease or condition is contraindications to chemoradiotherapy (e.g., active infection, 6 months after myocardial infarction, symptomatic...
See the full eligibility criteria
- Cervical cancer confirmed by histopathology incloud squamous cell carcinoma, adenocarcinoma and adenosquamous carcinoma
- FIGO stage IB3, IIA2, IIB-IVA patients in 2018
- Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect reached CR after treatment
- Aged 18-75 years
- PS score 0-1
- Serum hemoglobin \>=100\ 10\^9/L, blood platelet \>= 100000/μL, absolute count of neutrophils\>=1500/μL; 7.Serum creatinine \ = 60 ml/min; 8.Serum bilirubin \<=1.5 UNL, AST (SGOT) and ALT (SGPT)\<= 1.5 UNL
- Sign a formal informed consent to show that they understand that the study is in line with hospital and national policies .Estimated total survival \> 6 months.
- Locally advanced cervical cancer patients received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment after diagnosis, and the effect unreached CR after...
- Patients who have received neoadjuvant chemotherapy and surgery
- Patients with cognitive impairment
- Patients with any distant metastases
- Patients with any other malignancy within 5 years
- Any other disease or condition is contraindications to chemoradiotherapy (e.g., active infection, 6 months after myocardial infarction, symptomatic heart disease, including unstable angina, congestive heart failure or...
- Severe bone marrow dysfunction
- Patients with bleeding tendency
- Drug abusers or alcohol addicts
- Those who are known to have a third or fourth degree allergic reaction to any treatment in the study
The study team makes the final eligibility decision.
Where it's taking place
- Liuzhou, Guangxi, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Liuzhou, Guangxi, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.